Navrogen Inc. and Lonza Sign Agreement to Use Lonza’S GS Gene Expression System® for Navrogen’s Anti-HIO Targeting Agents
Navrogen Inc. and Lonza Pharma & Biotech announced today that they have entered a licensing agreement for the production of Navrogen's biotherapeutics using Lonza’s GS Xceed Expression System. Navrogen...
Read More
October 1, 2019
Navrogen Enters into CRADA with the U.S. National Cancer Institute to Develop Agents to Overcome Tumor-Mediated Immunosuppression
Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI). The CRADA is focused...
Read More
September 17, 2019
Navrogen Announces the Closing of $3.2M Funding to Support its Humoral Immuno-Oncology Platform Discovery Technologies and Preclinical Pipeline
Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing...
